Tumor Necrosis Factor (TNF) is central to the pathogenesis of many inflammatory diseases, acting primarily through the p55 Tumor Necrosis Factor Receptor 1 (TNFR1). Biologic agents have successfully targeted TNFR1 in rheumatoid arthritis and other inflammatory diseases. We are working with the Genetics and Genomics Branch in NHGRI to understand the pathophysiology of inflammation in patients with the TNF Receptor Associated Periodic Syndrome (TRAPS) a genetic autoinflammatory disease associated with dominant mutations in TNFR1. How TNFR1 mutations predispose to inflammation is not known. Blockade of TNF with biologic agents is only partially effective in treating the symptoms of TRAPS. We have found that TNFR1 mutant molecules associated with TRAPS are misfolded and accumulate in the endoplasmic reticulum. In more recent work, we have found that TNFR1 protein accumulates intracellularly in TRAPS patient PBMC and knock-in mice harboring two independent TRAPS associated TNFR1 mutations. Presence of the mutant TNFR1 protein specifically MAP-Kinase signaling, while NF-kB activation was not affected. Cells from heterozygous TNFR1 mutant mice exhibited elevated production of pro-inflammatory cytokines and systemic hypersensitivity to LPS, and TRAPS patient PBMC were hyper-responsive to low-dose LPS. In contrast, homozygous TNFR1 mutant mice were resistant to LPS-induced septic shock similarly to TNFR1 deficient mice. Hyperactivation of MAP kinases and enhanced inflammatory signaling is dependent mitochondrial generation of reactive oxygen species, identifying mitochondrial ROS as a possible therapeutic target in TRAPS.These results shed new light on the pathogenesis of TRAPS and identify novel strategies for anti-inflammatory treatment in TRAPS and other inflammatory diseases.

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zip Code
Jha, Smita; Fratzl-Zelman, Nadja; Roschger, Paul et al. (2018) Distinct clinical and pathological features of melorheostosis associated with somatic MAP2K1 mutations. J Bone Miner Res :
Kang, Heeseog; Jha, Smita; Deng, Zuoming et al. (2018) Somatic activating mutations in MAP2K1 cause melorheostosis. Nat Commun 9:1390
Traba, Javier; Geiger, Sarah S; Kwarteng-Siaw, Miriam et al. (2017) Prolonged fasting suppresses mitochondrial NLRP3 inflammasome assembly and activation via SIRT3-mediated activation of superoxide dismutase 2. J Biol Chem 292:12153-12164
Zhou, Yebin; Chen, Bo; Mittereder, Nanette et al. (2017) Spontaneous Secretion of the Citrullination Enzyme PAD2 and Cell Surface Exposure of PAD4 by Neutrophils. Front Immunol 8:1200
Zilberman-Rudenko, Jevgenia; Shawver, Linda Monaco; Wessel, Alex W et al. (2016) Recruitment of A20 by the C-terminal domain of NEMO suppresses NF-?B activation and autoinflammatory disease. Proc Natl Acad Sci U S A 113:1612-7
Zhou, Qing; Wang, Hongying; Schwartz, Daniella M et al. (2016) Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nat Genet 48:67-73
Richard, Arianne C; Ferdinand, John R; Meylan, Fran├žoise et al. (2015) The TNF-family cytokine TL1A: from lymphocyte costimulator to disease co-conspirator. J Leukoc Biol 98:333-45
Traba, Javier; Kwarteng-Siaw, Miriam; Okoli, Tracy C et al. (2015) Fasting and refeeding differentially regulate NLRP3 inflammasome activation in human subjects. J Clin Invest 125:4592-600
Agyemang, Amma F; Harrison, Stephanie R; Siegel, Richard M et al. (2015) Protein misfolding and dysregulated protein homeostasis in autoinflammatory diseases and beyond. Semin Immunopathol 37:335-47
Geiger, Sarah S; Fagundes, Caio T; Siegel, Richard M (2015) Chrono-Immunology: Progress and Challenges in Understanding Links between the Circadian and Immune Systems. Immunology :

Showing the most recent 10 out of 19 publications